Back To: Home



GSK, GlycoVaxyn in bacterial vaccine collaboration
February 2013

ZURICH-SCHLIEREN, SwitzerlandóGlaxoSmithKline Biologicals (GSK) recently announced a collaboration with vaccine developer GlycoVaxyn AG to develop new bacterial vaccines employing GlycoVaxyn's bio-conjugation technology.
"GlycoVaxyn's technology is designed to enable or improve the development of anti-bacterial conjugate vaccines by in-vivo synthesis of protein-polysaccharide complexes in E. coli, via recombinant DNA technology," said Michael Wacker, co-founder and chief scientific officer of GlycoVaxyn. "This technology could potentially broaden the range of anti-bacterial vaccines as we target our vaccine development to previously unattainable bacterial pathogens."  
The agreement includes an undisclosed set of pathogen targets in the field of bacterial vaccines. GSK retains an option to obtain an exclusive license on these targets during the three-year term of the collaboration and to extend both the term as well as scope of the collaboration. GlycoVaxyn receives an upfront payment and an equity investment. In addition, GlycoVaxyn is eligible to receive milestone payments and royalties on licensed vaccine candidates. Financial terms were not disclosed.
"This first collaboration with a vaccine industry leader confirms the potential of our platform to generate new complex vaccines," said Philippe Dro, CEO of GlycoVaxyn. "It was made possible because of our shared passion for innovation and discovering vaccines. We are looking forward to working with GlaxoSmithKline Biologicals to develop and bring to market important new vaccines that have the potential to save or change the lives of millions of people."



Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.